Utrecht, The Netherlands
AM-Pharma is a biopharmaceutical company developing a biotherapeutic for the treatment of Sepsis Associated Acute Kidney Injury (SA-AKI). The company successfully completed a phase 2 study and has initiated the global phase III REVIVAL pivotal study of recombinant human Alkaline Phosphatase in 1400 patients in more than 100 hospitals in twelve countries in Europe and the United States. SA-AKI is a major unmet medical need which involves an inflammatory process in the kidney which can lead to complete loss of renal function and affects annually approximately 3 million patients in Europe, US and Japan and is associated with the death of 700.000 patients per year.
Gilde invested to finance the phase II clinical study in 2014 and subsequently participated in the €139M financing round in 2020 to finance the REVIVAL phase III study.
AM-Pharma is located in Utrecht (Netherlands).